Sinovac Biotech has secured approval in China to move ahead with a human clinical trial on an inactivated vaccine candidate against the SARS-CoV-2 virus (novel coronavirus or COVID-19).
Intensity Therapeutics announced it has entered into a clinical trial collaboration agreement with Bristol Myers Squibb Company.
Hope Biosciences has been given clearance from the US Food and Drug Administration (FDA) to move ahead with a phase 2 trial to evaluate its investigational stem cell therapy in providing immune support against COVID-19.
Ridgeback Biotherapeutics announced clearance by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for an orally available antiviral compound, EIDD-2801, to begin human testing. This action by the MHRA allowed Ridgeback to commence Phase 1 in the UK.
Eli Lilly and Company (Lilly) has started clinical testing of its oral JAK1/JAK2 inhibitor OLUMIANT (baricitinib) and investigational candidate LY3127804 in separate COVID-19 trials.
Arrowhead Pharmaceuticals has filed an application for clearance to begin a Phase 1/2a clinical trial of ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF), which is a rare disease caused by genetic mutations that lead to progressive deterioration in lung function due to poor clearance of mucus and associated recurrent infections.
OncoImmune has received a study-may-proceed letter from the FDA for its Phase III clinical trial testing the safety and efficacy of CD24Fc for the treatment of hospitalized COVID-19 patients (SAC-COVID).
CROMSOURCE, an international contract research organization (CRO) with its global headquarters in Verona, Italy, has announced that it has initiated its first COVID-19 trial on behalf of a European pharmaceutical company.
The Montreal Heart Institute (MHI) Research Centre has collaborated with New York City’s NYU Grossman School of Medicine for a new COVID-19 clinical study.
GlaxoSmithKline (GSK) said that its asthma drug Nucala (mepolizumab) has succeeded in the phase 3 SYNAPSE trial in patients with nasal polyps associated with chronic rhinosinusitis (CRSwNP).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.